Synovial fluid mononuclear cells (SFMC) from patients with active rheumatoid arthritis characteristically respond poorly to mitogens. In this study, mitogenic antibodies reactive with the CD3(T3) antigen on human T lymphocytes were used to analyze the basis for the deficiency. OKT3-induced proliferation and release of interleukin 1 (ILiA) and interleukin 2 (IL-2) from SFMC were depressed in all patients. Purified IL-1 or recombinant IL-2 restored proliferative responses in SFMC and increased IL-2 receptor density. Exogenous IIL-also enhanced IL-2 release.
Monoclonal antibodies against the CD3(T3) molecular complex, which is exclusively present on T lymphocytes (7, 8) , are potent mitogens (9) . The cellular interactions leading to anti-CD3-induced T cell proliferation are well defined. The anti-CD3 antibodies bind specifically to their corresponding antigen on the T cell surface, whereas the Fc portion binds to Fc receptors on monocytes. Both events are required for anti-CD3-triggered T cell activation (10) (11) (12) . The T cell-monocyte interaction, presumably by a cross-linking event, induces interleukin 1 responsiveness and the presence ofIL-I is important for expression of receptors for interleukin 2 (IL-2), the release of IL-2, and ultimately IL-2-dependent cellular proliferation (13, 14) .
In the present investigation we have used anti-CD3 antibodies in order to examine these activation events in lymphocytes from RA blood and synovial fluid. The results indicate that the depressed mitogenic responses of RA lymphocytes are mediated predominantly by a specific inhibitor of IL-1.
Methods
Patient selection and characteristics. Heparinized peripheral blood was obtained from 22 healthy volunteers and patients with classical RA according to American Rheumatism Association criteria (15). Paired synovial fluid and peripheral blood samples were obtained from 19 patients with RA. Their biological parameters and medications are shown in Table I . An additional nine RA synovial fluid specimens came from subjects whose blood was not available.
Lymphocyte isolation and culture. Mononuclear cells were isolated from synovial fluid and peripheral blood by Ficoll-Hypaque densitygradient sedimentation (16) . Lymphocytes were cultured in RPMI-1640 medium supplemented with 5% heat-inactivated (56°C, 30 min) fetal bovine serum, 100 U/ml penicillin, 100 Ag/ml streptomycin, 2 [Methyl-3H~thymidine (1 uCi/well) was added during the last 4 h of incubation. The cells were collected on glass fiber filters, and radioactivity was assessed by liquid scintillation spectrometry.
Sources ofIL-I, IL-2, and antibodies. The IL-1 used in these studies was purified from cultures of human adherent blood monocytes as previously described using a combination of immunoadsorption and gel filtration ( 17) . When separated by charge (chromatofocusing or isoelectric focusing), this IL-, contained predominantly the pI 7 form. The purified material was assayed for the production of fever in rabbits and for lymphocyte-activating factor (LAF). The IL-1 used in these studies contained -100 U/ml where a unit is defined as the amount of IL-I/ml which doubled the proliferative responses of murine thymocytes to suboptimal concentrations of PHA. The antibody to IL-1 has been described previously (18 The levels of IL-I and IL-2 activities in the OKT3-stimulated cultures correlated well with the proliferative responses (Table  II) . Again, lymphocytes from RA patients and normal subjects released markedly different amounts of the two lymphokines after stimulation with 0.1 and 0.01 ng/ml OKT3 antibody.
Decreased proliferative responses in synovial fluid lymphocytes. Mononuclear cells from RA synovial fluids (SFMC) responded very weakly to OKT3 as compared with autologous PBMC (P < 0.001; Fig. 1 ). The low response occurred throughout a wide dose range (Table III) . The spontaneous proliferation (no added OKT3) of synovial fluid cells (1,592±1,188 cpm) was not significantly (P > 0.05) different from that of peripheral blood lymphocytes (1,136±946 cpm). Cell viability as estimated by trypan blue exclusion exceeded 90% in both SFMC and PBMC after 3 d in culture. Such variables as disease duration, disease activity, or medications did not appear to account specifically for the SFMC-impaired proliferation (cf. Table I) .
To exclude the possibility that the low response of SFMC was related to the particular IgG subclass of the anti-CD3 antibody used, we compared the effects oftwo anti-CD3 antibodies, Leu 4 (IgG1) and OKT3 (IgG2,). The proliferative responses of RA SFMC were severely depressed ( Fig. 1) with both antibodies. The Leu 4 monoclonal antibody will not activate the PBMC from -40% of normal donors (10, 12, 24 Effects of indomethacin and ofpreincubation on OKT3-induced proliferation. Activated cells in synovial fluid may release prostaglandins which can inhibit lymphocyte responses, particularly the secretion of IL-2 (25) . To evaluate whether prostaglandins were involved in the low proliferative responses observed, OKT3-stimulated PBMC and SFMC were cultured with indomethacin (1-10 tg/ml), an inhibitor of prostaglandin synthesis. Under these conditions proliferation of PBMC was augmented by only 34% and that of synovial cells by 28% (data not shown). The difference between the responses of cells from synovial fluid and blood remained significant. Cells in the synovial fluid are exposed in vivo to immunoglobulin aggregates, which may block Fc receptors on monocytes and thereby prevent OKT3 mitogenesis (26). Therefore, we preincubated SFMC for 24, 48, and 74 h in medium alone before the addition of OKT3 in order to permit shedding of immunoglobulins and clearing ofFc receptors. The preincubation did not alter the low proliferative response of SFMC (data not shown).
Production ofinterleukins by OKT3-stimulated PBMC and SFMC. Supernatants of PBMC and SFMC cultures stimulated with OKT3 (1 ng/ml) were harvested after 24 and 48 h and assayed for IL-, and IL-2 activities, respectively. The interleukin results corresponded remarkably with the proliferative responses (Figs. 2 and 3 ). IL-I and IL-2 activities were markedly lower in SFMC culture supernatants as compared with PBMC. The supernatants of SFMC did not have toxicity for the cells used in the bioassays. They impaired neither the proliferation of mouse thymocytes stimulated with 10 ptg/ml PHA, nor the proliferative responses of CTLL-2 to recombinant human or rat IL-2 (results not shown).
Exogenous purified IL-I at 32 U/ml caused a threefold increase in OKT3-induced IL-2 secretion from SFMC. Under these conditions, therefore, IL-2 levels in SFMC and PBMC super- natants became much more similar. In each case, the IL-2 activity could be neutralized with the anti-IL-2 antibody (Fig. 3) . The rising baseline of unneutralized counts per minute was possibly attributable to unknown contaminants in the IL-I preparation used.
IL-2 receptor expression and modulation by interleukins. SFMC and PBMC were stained when freshly isolated, or were cultured with OKT3 (1 ng/ml) or with medium alone for 48 h. 22 .6% in SFMC.
We then tested whether addition of exogenous interleukins would improve the proliferative responses and increase IL-2 receptor expression. The effects of recombinant human IL-2 at 7.5-30 U/ml and of purified IL-I at 8-32 U/ml are shown in Table IV and Fig. 4 . The addition of neither IL-I nor IL-2 increased significantly the number ofIL-2 receptor-positive cells in the PBMC, and affected minimally or not at all the responses to OKT3. Consistent with this, the lymphokines had only modest effects on the proliferative responses of the PBMC (Fig. 4) . In SFMC cultures, however, the lymphokine additions had a much more substantial effect (Fig. 4 and Table III ). The addition of IL-2 alone induced modest proliferation of SFMC in the absence of OKT3 (Fig. 4 B) . This is consistent with the intrinsic expression ofIL-2 receptors on these cells (Table IV) -Iincreased responses ofthe SFMC to OKT3 (1 ng/ml). With both, the increase was dose-dependent. At 30 U/ml ofIL-2, the OKT3-induced proliferation of SFMC was close to that of PBMC (Fig.  4 B) . Purified IL-l by itself did not trigger significant levels of proliferation.
IL-I inhibitor in culture supernatants from RA PBMC and SFMC. Supernatants from RA PBMC and SFMC cultured with or without OKT3 were tested for neutralization of a standard IL-l preparation. Fig. 5 shows that supernatants from both types ofcells contained a factor that neutralizes IL-1. However, much higher concentrations of the IL-I inhibitor were detected in SFMC cultures. The inhibitor activity decreased after OKT3 stimulation, but still persisted in high titer in SFMC cultures (Fig. 5) . It was not detectable in supernatants of normal PBMC cultures. Culture supernatants from RA SFMC did not neutralize the effect of purified or recombinant human IL72 on CTLL-2 cells (Table V) we depleted SFMC of monocytes by plastic adherence and subsequent carbonyl-iron treatment. The adherent cells were dislodged from the plastic surfaces with EDTA and cultured in parallel with SFMC and monocyte-depleted SFMC. Table VII shows that the IL-I inhibitor activity is predominantly derived from the monocyte-enriched population.
In an attempt to dissociate IL-I from the IL-I inhibitor(s), SFMC culture supernatants were chromatographed on phosphocellulose columns. After elution with a linear salt gradient (0.1-1 M), fractions were dialyzed against RPMI and tested on mouse thymocytes for IL-I activity. The IL-I activity eluted as a single peak at 0.3 M NaCl (Fig. 6 ) and was neutralized with the anti-IL-l antibody. The IL-l inhibitory activity did not bind to phosphocellulose and eluted with the void volume ofthe column (Fig. 6) . Thus, SFMC supernatants do contain biologically active IL-l, which can be detected after separation from the IL-I inhibitor(s).
Mixing of lymphocytes and monocytes from blood and synovialfluid. Having demonstrated that synovial fluid monocytes release much higher levels of IL-I inhibitor activity than blood monocytes, we tested various combinations ofpurified lymphocytes and monocytes. PBMC and SFMC from the same patient were partially depleted of monocytes by plastic adherence. Residual monocytes were removed by carbonyl-iron treatment. The adherent cells were dislodged with trypsin-EDTA and recombined with lymphocytes. Table VIII shows that both monocytedepleted PBMC and SFMC, as expected, did not respond to OKT3. When recombined with 10% blood monocytes, blood lymphocytes (two ofthree experiments) gave a high proliferative response, but with monocytes from synovial fluid, they uniformly R060-C - 40 .. showed low responses. With synovial fluid monocytes, synovial fluid lymphocytes gave a characteristically low proliferative response, but with blood monocytes they gave much higher responses. These results thus demonstrate that the poor mitogen Results are expressed as percent inhibition of the activity of 10 U/mi IL-i on mouse thymocytes. Culture supernatants from RA SFMC were added to mouse thymocytes stimulated with 10 U/ml IL-I and to CTLL-2 cells stimulated with 7.5 U/mi IL,2. Data shown are mean counts per minute±SEM of triplicates from four experiments. PBMC from normal donors were cultured in medium alone, or were stimulated with OKT3 (1 ng/ml) with simultaneous addition of 0.4-25% of RA SFMC culture supernatants and/or 8-32 U/ml of purified IL-1. Proliferation was assessed by [3H]thymidine incorporated after 72 h. Data are shown as mean counts per minute±SEM of two experiments. incubated with immobilized anti-T3 antibody (64.1) is in accord with these results ( 13) .
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In control experiments with PBMC, IL-2 receptor expression and/or proliferation increased very little after addition of exogenous IL-1 or IL-2, although they did significantly so with SFMC. Mixing experiments with purified monocytes and lymphocytes from blood and synovial fluid showed that synovial fluid lymphocytes gave a much higher proliferative response in the presence of autologous blood monocytes. Conversely, blood lymphocytes gave a low response in the presence of autologous synovial monocytes. In other experiments, synovial fluid monocytes were shown to be a rich source and blood monocytes a weak source of an IL-1 inhibitor. Collectively, these results strongly suggest that the defective proliferative and IL-2 secretory responses of OKT3-stimulated SFMC from RA patients are largely attributable to a deficiency in functional IL-I activity.
The importance of IL-1 in anti-CD3 mitogenesis is demonstrated by several experiments that will be reported separately (Lotz, M., J. Bentin, and C. D. Tsoukas, unpublished data). Thus, the addition ofantibody against IL-I to OKT3 stimulated normal PBMC reduces the proliferative response. Furthermore, IL-I is not detectable in Leu 4-stimulated PBMC of Leu 4 nonresponders. Finally, soluble OKT3 did not induce IL-I from isolated monocytes, but did so when both monocytes and T cells were present, indicating that IL-1 release after OKT3 is the result of a monocyte-T cell interaction and not due simply to a contaminant in the antibody preparation.
We were able to explain the low IL-I activity in RA cultures on the basis of a specific IL-l inhibitor. The IL-I inhibitor was detected in large quantities in SFMC cultures. Its action was selective for IL-I, in that it neutralized neither purified nor recombinant human IL-2. The inhibitor(s) was not a prostaglandin, nor were prostaglandins apparently involved in its induction. The inhibitor was not nonspecifically toxic to mouse thymocytes. SFMC culture supernatants with IL-I inhibitory activity decreased OKT3-induced proliferation of normal PBMC. This effect was overcome by purified exogenous IL-1.
Fractionation of SFMC culture supernatants on phosphocellulose allowed separation of biologically active IL-l from the IL-1 inhibitor. Several factors that neutralize IL-I have been described. Epstein-Barr virus-transformed B cell lines released a 95-kD protein that blocks IL-1 effects on mature T lymphocytes and thymocytes (31). We have also seen an IL-I inhibitor in the supernatants of RA PBMC infected in vitro with Epstein-Barr virus (32) . During endotoxin fever, human serum contains a factor that inhibits IL-l effects on mouse thymocytes (33) . Furthermore, in the urine offebrile patients a 20-40-kD glycoprotein was identified which specifically blocks IL-I-induced thymocyte proliferation (34) . Synovial fluid also contains a factor that masks IL-l activity, but this has not been characterized (35) . Arend et al. (36) induced the production of a 22-kD IL-1 inhibitor by culturing human monocytes on adherent immune complexes or antibodies. Cytomegalovirus infection of monocytes and a monocytic cell line caused release of an IL-1-specific inhibitor (37) . Thus, a variety of IL-I inhibitors have been described in vivo and in vitro. To ascertain the biochemical and immunologic relationships of the different IL-I inhibitors will require their purification, the preparation of monospecific antibodies to them, and characterization of their genetic sources. The prominent feature of the IL-I inhibitors is that they appear regularly during inflammatory responses induced by diverse stimuli. Perhaps immune complexes or a viral agent represent the eventual stimulus for IL-I inhibitor production in all cases. In this fashion, products of an inflammatory response may control T lymphocyte activation and lymphokine production via a normal feedback mechanism.
In RA patients, lymphocyte proliferation and lymphokine secretion in the synovial fluid may be dampened by the IL-l inhibitor(s). However, it remains unclear whether this is a deleterious or beneficial phenomenon. Certainly the inhibitor(s) should impair T cell-mediated inflammatory responses. At the same time the resultant T cell immunodeficiency might facilitate the persistence of inciting agents and release autoantibody-secreting B cells from regulatory control. An analysis ofthe effects of the IL-l inhibitor(s) on T cell-regulated autoantibody responses, and on the immune response to environmental pathogens, warrants further detailed study.
We do not know whether there is anything specific about the IL-I inhibitor for RA synovitis as compared with other synovitic disease. We do know, however, that the appearance ofan IL-l inhibitor in the supernatants ofEpstein-Barr virus-infected PBMC is not limited to RA, but may occur in other autoimmune diseases, although not in normal controls (38) .
